VivoPower PLC logo

VIVO

VivoPower PLC · NASDAQ

Website
Market cap
$68.5M

VivoPower PLC (VIVO) is a Power Generation company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for VIVO, including 4 press releases and news items, 1 dividend update and 1 SEC filing. The most recent was published Nov 13, 2026.

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H. pylori, and certain foodborne pathogens; respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry assays for testing elevated levels of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. The company has a strategic collaboration with DiaSorin Inc. to sell H. pylori tests. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.

VIVO rankings

Financial highlights

Full financials
Revenue, FY2026
$2.54M
Revenue growth
+4072.1%
Net income, FY2026
-$49.73M
Net margin
-1954.1%
Cash
$2.02M

For fiscal 2026 (ended Jun 30, 2026), from SEC filings. Not investment advice.

News · 26 weeks36+200%
2026-05-24: 02026-05-31: 12026-06-07: 22026-06-14: 12026-06-21: 32026-06-28: 52026-07-05: 52026-07-12: 22026-07-19: 22026-07-26: 22026-08-02: 22026-08-09: 02026-08-16: 22026-08-23: 12026-08-30: 02026-09-06: 02026-09-13: 02026-09-20: 02026-09-27: 02026-10-04: 02026-10-11: 12026-10-18: 12026-10-25: 02026-11-01: 32026-11-08: 32026-11-15: 0
2026-05-242026-11-15
Mix1190d
  • Other5(45%)
  • SEC Filings3(27%)
  • M&A1(9%)
  • Dividends1(9%)
  • Earnings1(9%)
Activity · 52 weeks5341 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

VIVO FAQ

10 questions
  • What does VivoPower PLC do?
    Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard...
  • What is the latest news on VIVO?
    In the last 30 days Quantisnow tracked 7 wire items for VIVO: 4 press releases and news items, 1 dividend update, 1 SEC filing and 1 earnings update. The most recent was published on November 13, 2026.
  • What is VIVO revenue?
    VivoPower PLC (VIVO) reported $2.54M of revenue for fiscal 2026 (ended Jun 30, 2026). That is up 4072.1% from the year before.
  • Is VIVO profitable?
    No. VivoPower PLC reported a net loss of $49.73M for fiscal 2026 (ended Jun 30, 2026).
  • How much cash and debt does VIVO have?
    VivoPower PLC reported $2.02M in cash and cash equivalents and $28.74M of debt on its most recent balance sheet in SEC filings.
  • Where does VIVO stock trade?
    VivoPower PLC (VIVO) is listed on NASDAQ.
  • What sector and industry is VIVO in?
    VivoPower PLC operates in the Utilities sector, Power Generation industry.
  • What are analysts saying about VIVO?
    VivoPower PLC has had 3 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $30.00 price target on 2022-02-07. Recent price targets range from $27.00 to $30.00.
  • What companies are similar to VIVO?
    Notable peers in the same industry include ABT (Abbott Laboratories), QDEL (QuidelOrtho Corporation), DHR (Danaher Corporation), BIO (Bio-Rad Laboratories Inc.). Compare VIVO side-by-side with any of them on Quantisnow.
  • How can I track VIVO on Quantisnow?
    Quantisnow aggregates VivoPower PLC's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VIVO to receive live email and push alerts on every new disclosure.